fregime
TODAYSTOCKSARCHIVE
Sign inFollow your stocks

What actually happened to the stocks you care about: every claim cited, corroboration counted, never opinions.

Development · 26 Aug 2026

ZYDUSLIFE, full dossier

Zydus Lifesciences Limited reported Q4 FY26 revenues of Rs. 75,870 million, up 16.2% year-over-year, with EBITDA of Rs. 25,544 million, up 20.2% year-over-year, and EBITDA margin of 33.7%, up 110 basis points year-over-year.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

Zydus Lifesciences Limited reported Q4 FY26 revenues of Rs. 75,870 million, up 16.2% year-over-year, with EBITDA of Rs. 25,544 million, up 20.2% year-over-year, and EBITDA margin of 33.7%, up 110 basis points year-over-year.

bseindia.com19 May 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Zydus Lifesciences

₹1,150.00

▲ +2.27%

Close (EOD), as of 26 Aug 2026 · source

Full cited record →

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.